Pulmonary infectious complications associated with anti-TNFα therapy (infliximab) for rheumatoid arthritis

Internal Medicine

Volumn 45, Issue 10, 2006, Pages 685-688

  Imaizumi, Kazuyoshi ^a   Sugishita, Mihoko ^a   Usui, Miho ^a   Kawabe, Tsutomu ^b   Hashimoto, Naozumi ^a   Hasegawa, Yoshinori ^a  

^a NAGOYA UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

^b NAGOYA UNIVERSITY   (Japan)

Author keywords

Anti TNF therapy; Fiber optic bronchoscopy; Infliximab; Pneumocystis jiroveci (carinii) pneumonia; Rheumatoid arthritis; Tuberculosis

Indexed keywords

ANTIBIOTIC AGENT; CORTICOSTEROID; COTRIMOXAZOLE; DISEASE MODIFYING ANTIRHEUMATIC DRUG; ETHAMBUTOL; INFLIXIMAB; ISONIAZID; METHOTREXATE; NONSTEROID ANTIINFLAMMATORY AGENT; PYRAZINAMIDE; RIFAMPICIN;

AGED; ANAMNESIS; ARTICLE; CASE REPORT; CLINICAL FEATURE; COMPUTER ASSISTED TOMOGRAPHY; DIARRHEA; DISEASE COURSE; DISEASE DURATION; DISEASE SEVERITY; DRUG DOSE REGIMEN; DYSPNEA; FEMALE; FEVER; FIBEROPTIC BRONCHOSCOPY; HUMAN; HUMAN CELL; HUMAN TISSUE; LUNG INFILTRATE; LUNG LAVAGE; LUNG TUBERCULOSIS; LYMPHADENOPATHY; NEEDLE BIOPSY; PNEUMOCYSTIS JIROVECI; PNEUMOCYSTIS PNEUMONIA; RHEUMATOID ARTHRITIS; THORAX RADIOGRAPHY;

AGED; ANTIBODIES, MONOCLONAL; ARTHRITIS, RHEUMATOID; FEMALE; HUMANS; IMMUNOSUPPRESSIVE AGENTS; METHOTREXATE; OPPORTUNISTIC INFECTIONS; PNEUMOCYSTIS JIROVECI; PNEUMONIA, PNEUMOCYSTIS; TUBERCULOSIS, PULMONARY; TUMOR NECROSIS FACTOR-ALPHA;

EID: 33745197541     PISSN: 09182918     EISSN: 13497235     Source Type: Journal    
DOI: 10.2169/internalmedicine.45.1623     Document Type: Article

References (14)

1. Hochberg MC, Lebwohl MG, Plevy SE, Hobbs KF, Yocum DE. The benefit/risk profile of TNF-blocking agents: findings of a consensus panel. Semin Arthritis Rheum 34: 819-836, 2005.
2. Voulgari PV, Alamanos Y, Nikas SN, Bougias DV, Temekonidis TI, Drosos AA. Infliximab therapy in established rheumatoid arthritis: an observational study. Am J Med 118: 515-520, 2005.
3. Watanabe A. Infliximab and tuberculosis. Bunshi Ryumachi (Molecular Rheumatology) 2: 272-277, 2005 (in Japanese).
4. Keane J, Gershon S, Wise RP, et al. Tuberculosis associated with infliximab, a tumor necrosis factor α-neutralizing agent. N Engl J Med 345: 1098-1104, 2001.
5. Seddik M, Meliez H, Seguy D, Viget N, Cortot A, Colombel JF. Pneumocystis jiroveci (carinii) pneumonia following initiation of infliximab and azathioprine therapy in a patient with Crohn's disease. Inflamm Bowel Dis 10: 436-437, 2004 (Erratum in: Inflamm Bowel Dis 11: 705, 2005).
6. Velayos FS, Sandborn WJ. Pneumocystis carinii pneumonia during maintenance anti-tumor necrosis factor-alpha therapy with infliximab for Crohn's disease. Inflamm. Bowel Dis 10: 657-660, 2004.
7. Tai TL, O'Rourke KP, McWeeney M, Burke CM, Sheehan K, Barry M. Pneumocystis carinii pneumonia following a second infusion of infliximab. Rheumatology (Oxford) 41: 951-952, 2002.
8. Japanese Society for Tuberculosis and Japan College of Rheumatology. More active chemo-prevention. Kekkaku 79: 785-787, 2004 (in Japanese).
9. Gardam MA, Keystone EC, Menzies R, et al. Anti-tumor necrosis factor agents and tuberculosis risk: mechanisms of action and clinical management. Lancet Infect Dis 3: 148-155, 2003.
10. Gleeson F, Clarke E, Kelly S, et al. Diagnosis by EUS trucut biopsy of extrapulmonary tuberculosis in a patient with Crohn's disease treated with infliximab. Gastrointest Endosc 61: 489-492, 2005.
11. Kondo H, Ishikawa A. Post-marketing surveillance of Infliximab: Appearance rate and appearance pattern of side effect according to period. Bunshi Ryumachi (Molecular Rheumatology) 2: 259-264, 2005 (in Japanese).
12. Sandborn WJ. Optimizing anti-tumor necrosis factor strategies in inflammatory bowel disease. Curr Gastroenterol Rep 5: 501-505, 2003.
13. Krebs S, Gibbons RB. Low-dose methotrexate as a risk factor for Pneumocystis carinii pneumonia. Mil Med 161: 58-60, 1996.
14. Kaur N, Mahl TC. Pneumocystis carinii pneumonia with oral candidiasis after infliximab therapy for Crohn's disease. Dig Dis Sci 49: 1458-1460, 2004.